Biomarkers for Gastric Cancer Screening and Early Diagnosis

Cristina Herrera-Pariente, Sheyla Montori, Joan Llach, Alex Bofill, Eduardo Albeniz, Leticia Moreira, Cristina Herrera-Pariente, Sheyla Montori, Joan Llach, Alex Bofill, Eduardo Albeniz, Leticia Moreira

Abstract

Gastric cancer is one of the most common cancers worldwide, with a bad prognosis associated with late-stage diagnosis, significantly decreasing the overall survival. This highlights the importance of early detection to improve the clinical course of these patients. Although screening programs, based on endoscopic or radiologic approaches, have been useful in countries with high incidence, they are not cost-effective in low-incidence populations as a massive screening strategy. Additionally, current biomarkers used in daily routine are not specific and sensitive enough, and most of them are obtained invasively. Thus, it is imperative to discover new noninvasive biomarkers able to diagnose early-stage gastric cancer. In this context, liquid biopsy is a promising strategy. In this review, we briefly discuss some of the potential biomarkers for gastric cancer screening and diagnosis identified in blood, saliva, urine, stool, and gastric juice.

Keywords: diagnostic; gastric cancer; liquid biopsy; noninvasive biomarker; screening.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Scheme of some of the most important noninvasive biomarkers for gastric cancer diagnosis and screening.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Vogelaar I., Van Der Post R.S., van Krieken J., Spruijt L., Van Zelst-Stams W.A., Kets C.M., Lubinski J., Jakubowska A., Teodorczyk U., Aalfs C.M., et al. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. Eur. J. Hum. Genet. 2017;25:1246–1252. doi: 10.1038/ejhg.2017.138.
    1. Isaeva G., Isaeva R. Molecular methods for the detection of Helicobacter pylori. Minerva Biotecnol. 2021;32:182–187. doi: 10.23736/S1120-4826.20.02665-8.
    1. Van Cutsem E., Sagaert X., Topal B., Haustermans K., Prenen H. Gastric cancer. Lancet. 2016;388:2654–2664. doi: 10.1016/S0140-6736(16)30354-3.
    1. Asplund J., Kauppila J.H., Mattsson F., Lagergren J. Survival Trends in Gastric Adenocarcinoma: A Population-Based Study in Sweden. Ann. Surg. Oncol. 2018;25:2693–2702. doi: 10.1245/s10434-018-6627-y.
    1. Choi K.S., Jun J.K., Park E.-C., Park S., Jung K.W., Han M.A., Choi I.J., Lee H.-Y. Performance of Different Gastric Cancer Screening Methods in Korea: A Population-Based Study. PLoS ONE. 2012;7:e50041. doi: 10.1371/journal.pone.0050041.
    1. Jun J.K., Choi K.S., Lee H.-Y., Suh M., Park B., Song S.H., Jung K.W., Lee C.W., Choi I.J., Park E.-C., et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152:1319–1328.e7. doi: 10.1053/j.gastro.2017.01.029.
    1. Khanderia E., Markar S.R., Acharya A., Kim Y., Kim Y.-W., Hanna G.B. The Influence of Gastric Cancer Screening on the Stage at Diagnosis and Survival. J. Clin. Gastroenterol. 2016;50:190–197. doi: 10.1097/MCG.0000000000000466.
    1. Cubiella J., Aisa Á.P., Cuatrecasas M., Redondo P.D., Esparrach G.F., Marín-Gabriel J.C., Moreira L., Núñez H., López M.L.P., de Santiago E.R., et al. Documento de posicionamiento de la AEG, la SEED y la SEAP sobre cribado de cáncer gástrico en poblaciones con baja incidencia. Gastroenterol. Hepatol. 2021;44:67–86. doi: 10.1016/j.gastrohep.2020.08.004.
    1. Fernández-Esparrach G., Marín-Gabriel J.C., Redondo P.D., Núñez H., de Santiago E.R., Rosón P., Calvet X., Cuatrecasas M., Cubiella J., Moreira L., et al. Documento de posicionamiento de la AEG, la SEED y la SEAP sobre calidad de la endoscopia digestiva alta para la detección y vigilancia de las lesiones precursoras de cáncer gástrico. Gastroenterol. Hepatol. 2021;44:448–464. doi: 10.1016/j.gastrohep.2021.01.002.
    1. Matsuoka T., Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J. Gastroenterol. 2018;24:2818–2832. doi: 10.3748/wjg.v24.i26.2818.
    1. Feng F., Tian Y., Xu G., Liu Z., Liu S., Zheng G., Guo M., Lian X., Fan D., Zhang H. Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17:1–6. doi: 10.1186/s12885-017-3738-y.
    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69:89–95. doi: 10.1067/mcp.2001.113989.
    1. De Mattos-Arruda L., Olmos D., Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Futur. Oncol. 2011;7:1385–1397. doi: 10.2217/fon.11.122.
    1. Qian C., Ju S., Qi J., Zhao J., Shen X., Jing R., Yu J., Li L., Shi Y., Zhang L., et al. Alu-based cell-free DNA: A novel biomarker for screening of gastric cancer. Oncotarget. 2017;8:54037–54045. doi: 10.18632/oncotarget.11079.
    1. Kim K., Shin D.G., Park M.K., Baik S.H., Kim T.H., Kim S., Lee S. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: Diagnostic validity and significant reduction of cfDNA after surgical resection. Ann. Surg. Treat. Res. 2014;86:136–142. doi: 10.4174/astr.2014.86.3.136.
    1. Huang Z.-B., Zhang H.-T., Yu B., Yu D.-H. Cell-free DNA as a liquid biopsy for early detection of gastric cancer (Review) Oncol. Lett. 2020;21:1. doi: 10.3892/ol.2020.12264.
    1. Cohen J.D., Li L., Wang Y., Thoburn C., Afsari B., Danilova L., Douville C., Javed A.A., Wong F., Mattox A., et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247.
    1. Padmanabhan N., Ushijima T., Tan N.P.P. How to stomach an epigenetic insult: The gastric cancer epigenome. Nat. Rev. Gastroenterol. Hepatol. 2017;14:467–478. doi: 10.1038/nrgastro.2017.53.
    1. Hideura E., Suehiro Y., Nishikawa J., Shuto T., Fujimura H., Ito S., Goto A., Hamabe K., Saeki I., Okamoto T., et al. Blood Free-Circulating DNA Testing of Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer. Cancers. 2020;12:789. doi: 10.3390/cancers12040789.
    1. Miao J., Liu Y., Zhao G., Liu X., Ma Y., Li H., Li S., Zhu Y., Xiong S., Zheng M., et al. Feasibility of Plasma-Methylated SFRP2 for Early Detection of Gastric Cancer. Cancer Control. 2020;27:27. doi: 10.1177/1073274820922559.
    1. Alarcón M.A., Olivares W., Córdova-Delgado M., Muñoz-Medel M., De Mayo T., Carrasco-Aviño G., Wichmann I., Landeros N., Amigo J., Norero E., et al. The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer. Int. J. Mol. Sci. 2020;21:9472. doi: 10.3390/ijms21249472.
    1. Liu L., Yang X. Implication of Reprimo and hMLH1 gene methylation in early diagnosis of gastric carcinoma. Int. J. Clin. Exp. Pathol. 2015;8:14977–14982.
    1. Fernandes J., Michel V., Camorlinga-Ponce M., Gomez A., Maldonado C., DE Reuse H., Torres J., Touati E. Circulating Mitochondrial DNA Level, a Noninvasive Biomarker for the Early Detection of Gastric Cancer. Cancer Epidemiol. Biomark. Prev. 2014;23:2430–2438. doi: 10.1158/1055-9965.EPI-14-0471.
    1. Ueda T., Volinia S., Okumura H., Shimizu M., Taccioli C., Rossi S., Alder H., Liu C.-G., Oue N., Yasui W., et al. Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 2010;11:136–146. doi: 10.1016/S1470-2045(09)70343-2.
    1. Yao Y., Ding Y., Bai Y., Zhou Q., Lee H., Li X., Teng L. Identification of Serum Circulating MicroRNAs as Novel Diagnostic Biomarkers of Gastric Cancer. Front. Genet. 2021;11:591515. doi: 10.3389/fgene.2020.591515.
    1. Huang T., Song C., Zheng L., Xia L., Li Y., Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol. Cancer. 2019;18:1–11. doi: 10.1186/s12943-019-0967-5.
    1. Koga Y., Yasunaga M., Moriya Y., Akasu T., Fujita S., Yamamoto S., Matsumura Y. Exosome Can Prevent RNase from Degrading MicroRNA in Feces. J. Gastrointest. Oncol. 2011;2:215–222.
    1. Zheng G.-D., Xu Z.-Y., Hu C., Lv H., Xie H.-X., Huang T., Zhang Y.-Q., Chen G.-P., Fu Y.-F., Cheng X.-D. Exosomal miR-590-5p in Serum as a Biomarker for the Diagnosis and Prognosis of Gastric Cancer. Front. Mol. Biosci. 2021;8:1–10. doi: 10.3389/fmolb.2021.636566.
    1. Shi Y., Wang Z., Zhu X., Chen L., Ma Y., Wang J., Yang X., Liu Z. Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer. Int. J. Clin. Oncol. 2019;25:89–99. doi: 10.1007/s10147-019-01532-9.
    1. Hung P.-S., Chen C.-Y., Chen W.-T., Kuo C.-Y., Fang W.-L., Huang K.-H., Chiu P.-C., Lo S.-S. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS ONE. 2017;12:e0177346. doi: 10.1371/journal.pone.0177346.
    1. Wu J., Li G., Wang Z., Yao Y., Chen R., Pu X., Wang J. Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer. Dis. Mark. 2015;2015:1–8. doi: 10.1155/2015/435656.
    1. Zeng W., Zhang S., Yang L., Wei W., Gao J., Guo N., Wu F. Serum miR-101-3p combined with pepsinogen contributes to the early diagnosis of gastric cancer. BMC Med. Genet. 2020;21:1–7. doi: 10.1186/s12881-020-0967-8.
    1. Cheng J., Yang A., Cheng S., Feng L., Wu X., Lu X., Zu M., Cui J., Yu H., Zou L. Circulating miR-19a-3p and miR-483-5p as Novel Diagnostic Biomarkers for the Early Diagnosis of Gastric Cancer. Med. Sci. Monit. 2020;26:e923444. doi: 10.12659/MSM.923444.
    1. Zhu C., Ren C., Han J., Ding Y., Du J., Dai N., Dai J., Ma H., Hu Z., Shen H., et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br. J. Cancer. 2014;110:2291–2299. doi: 10.1038/bjc.2014.119.
    1. So J.B.Y., Kapoor R., Zhu F., Koh C., Zhou L., Zou R., Tang Y.C., Goo P.C.K., Rha S.Y., Chung H.C., et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021;70:829–837. doi: 10.1136/gutjnl-2020-322065.
    1. Sun H., Tang W., Rong D., Jin H., Fu K., Zhang W., Liu Z., Cao H., Cao X. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomark. 2018;21:299–306. doi: 10.3233/CBM-170379.
    1. Shao Y., Tao X., Lu R., Zhang H., Ge J., Xiao B., Ye G., Guo J. Hsa_circ_0065149 is an Indicator for Early Gastric Cancer Screening and Prognosis Prediction. Pathol. Oncol. Res. 2020;26:1475–1482. doi: 10.1007/s12253-019-00716-y.
    1. Huang M., He Y.-R., Liang L.-C., Huang Q., Zhu Z.-Q. Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer. World J. Gastroenterol. 2017;23:6330–6338. doi: 10.3748/wjg.v23.i34.6330.
    1. Ma S., Kong S., Gu X., Xu Y., Tao M., Shen L., Shen X., Ju S. As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway. Cancer Cell Int. 2021;21:1–14. doi: 10.1186/s12935-020-01701-1.
    1. Dong L., Qi P., Xu M.-D., Ni S.-J., Huang D., Xu Q.-H., Weng W.-W., Tan C., Sheng W.-Q., Zhou X.-Y., et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int. J. Cancer. 2015;137:1128–1135. doi: 10.1002/ijc.29484.
    1. Zhang K., Shi H., Xi H., Wu X., Cui J., Gao Y., Liang W., Hu C., Liu Y., Li J., et al. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics. 2017;7:213–227. doi: 10.7150/thno.16044.
    1. Lijun Q., Shao Y., Zhang X., Zheng T., Miao M., Qin L., Wang B., Ye G., Xiao B., Guo J. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumor Biol. 2015;36:2007–2012. doi: 10.1007/s13277-014-2807-y.
    1. Lin L.-Y., Yang L., Zeng Q., Wang L., Chen M.-L., Zhao Z.-H., Ye G.-D., Luo Q.-C., Lv P.-Y., Guo Q.-W., et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol. Cancer. 2018;17:84. doi: 10.1186/s12943-018-0834-9.
    1. Zhao R., Zhang Y., Zhang X., Yang Y., Zheng X., Li X., Liu Y., Zhang Y. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol. Cancer. 2018;17:68. doi: 10.1186/s12943-018-0817-x.
    1. Qin J., Yang Q., Ye H., Wang K., Zhang M., Zhu J., Wang X., Dai L., Wang P., Zhang J. Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer. J. Oncol. 2020;2020:1–10. doi: 10.1155/2020/9430737.
    1. Song Y., Wang J., Sun J., Chen X., Shi J., Wu Z., Yu D., Zhang F., Wang Z. Screening of Potential Biomarkers for Gastric Cancer with Diagnostic Value Using Label-free Global Proteome Analysis. Genom. Proteom. Bioinform. 2020;18:679–695. doi: 10.1016/j.gpb.2020.06.012.
    1. Suo J., Zhang D.Y., Tong W., Ye F., He L., Cui L., Cui M., Hu Y., Li W., Jiang J. Serum biomarker panels for diagnosis of gastric cancer. OncoTargets Ther. 2016;9:2455–2463. doi: 10.2147/OTT.S86139.
    1. Liu S., Cui M., Zang J., Wang J., Shi X., Qian F., Xu S., Jing R. SLC6A3 as a potential circulating biomarker for gastric cancer detection and progression monitoring. Pathol. Res. Pract. 2021;221:153446. doi: 10.1016/j.prp.2021.153446.
    1. Zhou B., Zhou Z., Chen Y., Deng H., Cai Y., Rao X., Yin Y., Rong L. Plasma proteomics-based identification of novel biomarkers in early gastric cancer. Clin. Biochem. 2020;76:5–10. doi: 10.1016/j.clinbiochem.2019.11.001.
    1. Loong T.H., Soon N.C., Mahmud N.R.K.N., Naidu J., Rani R.A., Hamid N.A., Elias M.H., Rose I.M., Tamil A.M., Mokhtar N.M., et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. Biomed. Rep. 2017;7:460–468. doi: 10.3892/br.2017.985.
    1. McNicholl A.G., Forné M., Barrio J., De la Coba C., González B., Rivera R., Esteve M., Fernández-Bañares F., Madrigal B., Gras-Miralles B., et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur. J. Gastroenterol. Hepatol. 2014;26:941–948. doi: 10.1097/MEG.0000000000000132.
    1. Aikou S., Ohmoto Y., Gunji T., Matsuhashi N., Ohtsu H., Miura H., Kubota K., Yamagata Y., Seto Y., Nakajima A., et al. Tests for Serum Levels of Trefoil Factor Family Proteins Can Improve Gastric Cancer Screening. Gastroenterology. 2011;141:837–845.e7. doi: 10.1053/j.gastro.2011.05.040.
    1. Choi B., Lee H.-J., Min J., Choe H.-N., Choi Y.-S., Son Y.-G., Ahn H.-S., Suh Y.-S., Goldenring J.R., Yang H.-K. Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer. Cancer Biomark. 2017;19:231–239. doi: 10.3233/CBM-160147.
    1. Huang Z., Zhang X., Lu H., Wu L., Wang D., Zhang Q., Ding H. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China. BMC Gastroenterol. 2014;14:74. doi: 10.1186/1471-230X-14-74.
    1. Altun E., Yildiz A., Cevik C., Turan G. The role of high sensitive C-reactive protein and histopathological evaluation in chronic gastritis patients with or without Helicobacter pylori infection. Acta Cir. Bras. 2019;34:e201900310. doi: 10.1590/s0102-865020190030000010.
    1. Chung H.W., Kim J.W., Lee J.-H., Song S.Y., Chung J.B., Kwon O.H., Lim J.-B. Comparison of the Validity of Three Biomarkers for Gastric Cancer Screening. J. Clin. Gastroenterol. 2009;43:19–26. doi: 10.1097/MCG.0b013e318135427c.
    1. He X.-X., Yang J., Ding Y.-W., Liu W., Shen Q.-Y., Xia H.H.-X. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: Potential role of MIF in gastric carcinogenesis. Gut. 2006;55:797–802. doi: 10.1136/gut.2005.078113.
    1. Pan K.-F., Formichella L., Zhang L., Zhang Y., Ma J.-L., Li Z.-X., Liu C., Wang Y.-M., Goettner G., Ulm K., et al. Helicobacter pyloriantibody responses and evolution of precancerous gastric lesions in a Chinese population. Int. J. Cancer. 2014;134:2118–2125. doi: 10.1002/ijc.28560.
    1. Yamamoto H., Watanabe Y., Sato Y., Maehata T., Itoh F. Non-Invasive Early Molecular Detection of Gastric Cancers. Cancers. 2020;12:2880. doi: 10.3390/cancers12102880.
    1. Kahroba H., Hejazi M.S., Samadi N. Exosomes: From carcinogenesis and metastasis to diagnosis and treatment of gastric cancer. Cell. Mol. Life Sci. 2019;76:1747–1758. doi: 10.1007/s00018-019-03035-2.
    1. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007;9:654–659. doi: 10.1038/ncb1596.
    1. Skog J., Würdinger T., Van Rijn S., Meijer D.H., Gainche L., Curry W.T., Jr., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature. 2008;10:1470–1476. doi: 10.1038/ncb1800.
    1. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A.J., Hopmans E.S., Lindenberg J.L., de Gruijl T.D., Würdinger T., Middeldorp J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. USA. 2010;107:6328–6333. doi: 10.1073/pnas.0914843107.
    1. Cheng L., Sharples R.A., Scicluna B.J., Hill A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles. 2014;3:23743. doi: 10.3402/jev.v3.23743.
    1. Zhang Y., Bi J., Huang J., Tang Y., Du S., Li P. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. Int. J. Nanomed. 2020;15:6917–6934. doi: 10.2147/IJN.S264498.
    1. Xiao Y., Zhong J., Zhong B., Huang J., Jiang L., Jiang Y., Yuan J., Sun J., Dai L., Yang C., et al. Exosomes as potential sources of biomarkers in colorectal cancer. Cancer Lett. 2020;476:13–22. doi: 10.1016/j.canlet.2020.01.033.
    1. Zhou B., Xu K., Zheng X., Chen T., Wang J., Song Y., Shao Y., Zheng S. Application of exosomes as liquid biopsy in clinical diagnosis. Signal. Transduct. Target. Ther. 2020;5:1–14. doi: 10.1038/s41392-020-00258-9.
    1. Li F., Yoshizawa J.M., Kim K.-M., Kanjanapangka J., Grogan T.R., Wang X., Elashoff D.E., Ishikawa S., Chia D., Liao W., et al. Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. Clin. Chem. 2018;64:1513–1521. doi: 10.1373/clinchem.2018.290569.
    1. Xu F., Jiang M. Evaluation of predictive role of carcinoembryonic antigen and salivary mRNA biomarkers in gastric cancer detection. Medicine. 2020;99:e20419. doi: 10.1097/MD.0000000000020419.
    1. Xiao H., Zhang Y., Kim Y., Kim S., Kim J.J., Kim K.M., Yoshizawa J., Fan L.-Y., Cao C., Wong D.T.W. Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. Sci. Rep. 2016;6:22165. doi: 10.1038/srep22165.
    1. Shu J., Yu H., Li X., Zhang D., Liu X., Du H., Zhang J., Yang Z., Xie H., Li Z. Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer. Oncotarget. 2017;8:35718–35727. doi: 10.18632/oncotarget.16082.
    1. Yoshizawa J.M., Schafer C.A., Schafer J.J., Farrell J.J., Paster B.J., Wong D.T.W. Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities. Clin. Microbiol. Rev. 2013;26:781–791. doi: 10.1128/CMR.00021-13.
    1. Spielmann N., Wong D.T. Saliva: Diagnostics and therapeutic perspectives. Oral Dis. 2010;17:345–354. doi: 10.1111/j.1601-0825.2010.01773.x.
    1. Ai J., Smith B., Wong D.T. Saliva Ontology: An ontology-based framework for a Salivaomics Knowledge Base. BMC Bioinform. 2010;11:302. doi: 10.1186/1471-2105-11-302.
    1. Bonne N.J., Wong D.T. Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med. 2012;4:82. doi: 10.1186/gm383.
    1. Rapado-González Ó., Martínez-Reglero C., Salgado-Barreira A., Takkouche B., López-López R., Suárez-Cunqueiro M.M., Muinelo-Romay L. Salivary biomarkers for cancer diagnosis: A meta-analysis. Ann. Med. 2020;52:131–144. doi: 10.1080/07853890.2020.1730431.
    1. Iwasaki H., Shimura T., Yamada T., Okuda Y., Natsume M., Kitagawa M., Horike S.-I., Kataoka H. A novel urinary microRNA biomarker panel for detecting gastric cancer. J. Gastroenterol. 2019;54:1061–1069. doi: 10.1007/s00535-019-01601-w.
    1. Shimura T., Dagher A., Sachdev M., Ebi M., Yamada T., Yamada T., Joh T., Moses M.A. Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer. Cancer Prev. Res. 2015;8:240–248. doi: 10.1158/1940-6207.CAPR-14-0229.
    1. Shimura T., Dayde D., Wang H., Okuda Y., Iwasaki H., Ebi M., Kitagawa M., Yamada T., Yamada T., Hanash S.M., et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br. J. Cancer. 2020;123:1656–1664. doi: 10.1038/s41416-020-01063-5.
    1. Chen Q., Hu Y., Fang Z., Ye M., Li J., Zhang S., Yuan Y., Guo C. Elevated Levels of Oxidative Nucleic Acid Modification Markers in Urine from Gastric Cancer Patients: Quantitative Analysis by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry. Front. Chem. 2020;8:606495. doi: 10.3389/fchem.2020.606495.
    1. Shirasu M., Touhara K. The scent of disease: Volatile organic compounds of the human body related to disease and disorder. J. Biochem. 2011;150:257–266. doi: 10.1093/jb/mvr090.
    1. Marimuthu A., O’Meally R.N., Chaerkady R., Subbannayya Y., Nanjappa V., Kumar P., Kelkar D.S., Pinto S.M., Sharma R., Renuse S., et al. A Comprehensive Map of the Human Urinary Proteome. J. Proteome Res. 2011;10:2734–2743. doi: 10.1021/pr2003038.
    1. Bax C., Taverna G., Eusebio L., Sironi S., Grizzi F., Guazzoni G., Capelli L. Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. Cancers. 2018;10:123. doi: 10.3390/cancers10040123.
    1. Bax C., Lotesoriere B.J., Sironi S., Capelli L. Bax Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways. Cancers. 2019;11:1244. doi: 10.3390/cancers11091244.
    1. Oshi M., Murthy V., Takahashi H., Huyser M., Okano M., Tokumaru Y., Rashid O., Matsuyama R., Endo I., Takabe K. Urine as a Source of Liquid Biopsy for Cancer. Cancers. 2021;13:2652. doi: 10.3390/cancers13112652.
    1. Qiao S.-X., Yuan M., Liu Y.-L., Lin X.-S., Zhang X.-P., Tobi M. Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9. Cancer Epidemiol. Biomark. Prev. 2003;12:1095–1099.
    1. Zhang B., Chen J.-Y., Chen D.-D., Wang G.-B., Shen P. Tumor type M2pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J. Gastroenterol. 2004;10:1643–1646. doi: 10.3748/wjg.v10.i11.1643.
    1. Shimura T. Novel Biomarkers of Gastrointestinal Cancer. Cancers. 2021;13:1501. doi: 10.3390/cancers13071501.
    1. Liu S., Dai J., Lan X., Fan B., Dong T., Zhang Y., Han M. Intestinal bacteria are potential biomarkers and therapeutic targets for gastric cancer. Microb. Pathog. 2021;151:104747. doi: 10.1016/j.micpath.2021.104747.
    1. Wu J., Zhang C., Xu S., Xiang C., Wang R., Yang D., Lu B., Shi L., Tong R., Teng Y., et al. Fecal Microbiome Alteration May Be a Potential Marker for Gastric Cancer. Dis. Mark. 2020;2020:1–17. doi: 10.1155/2020/3461315.
    1. Kon O.L., Yip T.-T., Ho M.F., Chan W.H., Wong W.K., Tan S.Y., Ng W.H., Kam S.Y., Eng A.K., Ho P., et al. The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med. Genom. 2008;1:54. doi: 10.1186/1755-8794-1-54.
    1. Virgilio E., Giarnieri E., Giovagnoli M.R., Montagnini M., Proietti A., D’Urso R., Mercantini P., Balducci G., Cavallini M. Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review. Anticancer. Res. 2018;38:613–616. doi: 10.21873/anticanres.12265.
    1. Huang L., Xu A. Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination. Front. Med. 2017;11:20–31. doi: 10.1007/s11684-016-0493-4.
    1. Yim S., Gultepe E., Gracias D.H., Sitti M. Biopsy using a Magnetic Capsule Endoscope Carrying, Releasing, and Retrieving Untethered Microgrippers. IEEE Trans. Biomed. Eng. 2014;61:513–521. doi: 10.1109/tbme.2013.2283369.
    1. Zhao A.-J., Qian Y.-Y., Sun H., Hou X., Pan J., Liu X., Zhou W., Chen Y.-Z., Jiang X., Li Z.-S., et al. Screening for gastric cancer with magnetically controlled capsule gastroscopy in asymptomatic individuals. Gastrointest. Endosc. 2018;88:466–474.e1. doi: 10.1016/j.gie.2018.05.003.
    1. Muretto P., Graziano F., Staccioli M.P., Barbanti I., Bartolucci A., Paolini G., Giordano D., Testa E., De Gaetano A. An endogastric capsule for measuring tumor markers ingastric juice: An evaluation of the safety and efficacy of a new diagnostic tool. Ann. Oncol. 2003;14:105–109. doi: 10.1093/annonc/mdg027.
    1. Muretto P., Ruzzo A., Pizzagalli F., Graziano F., Maltese P.E., Zingaretti C., Berselli E., Donnarumma N., Magnani M. Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. Ann. Oncol. 2008;19:516–519. doi: 10.1093/annonc/mdm493.
    1. Yamamoto H., Watanabe Y., Oikawa R., Morita R., Yoshida Y., Maehata T., Yasuda H., Itoh F. BARHL2 Methylation Using Gastric Wash DNA or Gastric Juice Exosomal DNA is a Useful Marker for Early Detection of Gastric Cancer in an H. pylori-Independent Manner. Clin. Transl. Gastroenterol. 2016;7:e184. doi: 10.1038/ctg.2016.40.
    1. Yu X., Luo L., Wu Y., Yu X., Liu Y., Yu X., Zhao X., Zhang X., Cui L., Ye G., et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med. Oncol. 2013;30:365. doi: 10.1007/s12032-012-0365-y.
    1. Zhang X., Cui L., Ye G., Zheng T., Song H., Xia T., Yu X., Xiao B., Le Y., Guo J. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumor Biol. 2012;33:2349–2355. doi: 10.1007/s13277-012-0497-x.
    1. Cui L., Zhang X., Ye G., Zheng T., Song H., Deng H., Xiao B., Xia T., Yu X., Le Y., et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119:1618–1626. doi: 10.1002/cncr.27903.
    1. Shao J., Fang P.-H., He B., Guo L.-L., Shi M.-Y., Zhu Y., Bo P., Zhen-Wen Z.-W. Downregulated MicroRNA-133a in Gastric Juice as a Clinicopathological Biomarker for Gastric Cancer Screening. Asian Pac. J. Cancer Prev. 2016;17:2719–2722.
    1. Shao Y., Li J., Lu R., Li T., Yang Y., Xiao B., Guo J. Global circular RNA expression profile of human gastric cancer and its clinical significance. Cancer Med. 2017;6:1173–1180. doi: 10.1002/cam4.1055.
    1. Zhou X., Liu J., Meng A., Zhang L., Wang M., Fan H., Peng W., Lu J. Gastric juice piR-1245: A promising prognostic biomarker for gastric cancer. J. Clin. Lab. Anal. 2020;34:e23131. doi: 10.1002/jcla.23131.
    1. Shao Y., Ye M., Bs X.J., Sun W., Ding X., Liu Z., Ye G., Zhang X., Xiao B., Guo J. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer. 2014;120:3320–3328. doi: 10.1002/cncr.28882.
    1. Shao Y., Ye M., Li Q., Sun W., Ye G., Zhang X., Yang Y., Xiao B., Guo J. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016;7:37812–37824. doi: 10.18632/oncotarget.9336.
    1. Yang Y., Shao Y., Zhu M., Li Q., Yang F., Lu X., Xu C., Xiao B., Sun Y., Guo J. Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer. Tumor Biol. 2015;37:1183–1188. doi: 10.1007/s13277-015-3903-3.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi